þÿ
...by analysis of such features as relationship to dose, relationship to drug concentration,disappearance on.....results of studies, by postmarketing experience, or by information on similar drugs.....metabolite concentrations is usually of interest, PD information is frequently collected in dose-response studies or together..
http://www.fda.gov/cder/guidance/4539E.pdf (score=100)

FDA LAUNCHES ONCOLOGY TOOLS WEBSITE - CDER WEBSITE OFFERS ACCESS TO...
...gov/cder/cancer, can be searched by specific types of cancer and by approved drug.....This will make it easier for consumers and patients to obtain information about different.....drug dose calculators. The Oncology Tools page was developed by the Division of Oncology Drug..
http://www.fda.gov/bbs/topics/NEWS/NEW00731.html (score=346)

þÿ
...information on drug activity is encouraged, as is further development of models that.....genetically toxic drug is not administered to a healthy volunteer for greater than one.....usually followed by clinical trials in which drug exposure increases by dose, duration..
http://www.fda.gov/cder/guidance/5518dft.pdf (score=94)

Guidance for Industry: Vaccinia Virus - Developing Drugs to Mitigate...
...information on drug activity is encouraged, as is further development of models that.....genetically toxic drug is not administered to a healthy volunteer for greater than one.....usually followed by clinical trials in which drug exposure increases by dose, duration..
http://www.fda.gov/cber/gdlns/vacciniadrugs.pdf (score=94)

CDER 2001 Report to the Nation
...Our systematic, adequate to preserve the drug product's identity, strength, potency.....information about prescription drugs when they pick up their prescriptions. We are.....effective human dose. The Sept. 11 terrorist attacks and the subsequent anthrax attacks..
http://www.fda.gov/cder/reports/rtn/2001/rtn2001.pdf (score=93)

Getting SMART: Drug Review in the Computer Age
...Well it might be things like drug dose, duration of dose, change in dose, cumulative dose, and.....Drug sponsors won't have to redesign their information systems, some of which are considered valuable trade secrets by the companies.....With the agency's encouragement, drug sponsors now furnish some or all of the information contained in an NDA in a format that can be..
http://www.fda.gov/fdac/features/895_smart.html (score=93)

Guidance for Industry: Vaccinia Virus — Developing Drugs to Mitigate...
...Developing such models could expedite the selection of an optimal drug dose regimen for human.....Use of existing animal models to provide preliminary information on drug activity is.....Therefore phase 1 trials are usually followed by clinical trials in which drug exposure increases by dose, duration..
http://www.fda.gov/cber/gdlns/vacciniadrugs.htm (score=93)

CDER 1999 Report to the Nation
...making from consumers, industry for prompt and thorough review of drug applications.....information about prescription drugs when they pick up their prescriptions.We are watching.....The drug is administered incorrectly or the wrong drug..or dose is administered. Remaining..
http://www.fda.gov/cder/reports/rtn99.pdf (score=92)

MDI and DPI Drug Products
...The guidance sets forth information that should be provided to ensure continuing drug.....also known as oral and nasal metered dose inhalers respectively or MDIs) and inhalation.....establish a set of criteria to which a drug substance or drug product should conform using..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=37)

April 2000 Safety-Related Drug Labeling Changes
...To reduce the chance of a drug-drug interaction, cyclosporine should be taken at least 2 hours.....Consult the compete prescribing information for Agenerase Oral Solution for full.....The recommended daily dose of Agenerase Oral Solution of 22.5 mg/kg twice daily..
http://www.fda.gov/medwatch/safety/2000/apr00.htm (score=36)

þÿ
...nursing or to discontinue the drug, taking into account the importance of the drug to the.....Following single intravenous doses, dose-proportional pharmacokinetics were shown in the.....Information for Patients.. MOBIC, like other drugs of its class, can cause discomfort and..
http://www.fda.gov/cder/foi/label/2000/20938lbl.pdf (score=35)

Document Information Page
...dose that produced mean plasma drug levels about 30 times higher than the mean plasma drug.....Information for Patients.. Patients should be advised about substances they should not.....180 mg/kg/day, a dose that produced mean plasma drug levels about 12 times higher than the..
http://www.fda.gov/cder/foi/label/2002/19766s56lbl.pdf (score=35)

þÿ
...drug is physiologically concentrated or in situations where high dosage of drug can be.....The pharmacokinetics of a single 320 mg dose of gemifloxacin were also studied in patients.....susceptibility information are available, they should be considered in selecting or..
http://www.fda.gov/cder/foi/label/2003/21158_factive_lbl.pdf (score=35)

Regulatory Information
...Human Drug Current Good Manufacturing Practice Notes is a periodic memo on Current Good.....This FDA Office of Public Affairs page provides information on IRB operations and clinical.....Since most of the metered-dose inhalers (MDIs) available in the United States contain..
http://www.fda.gov/cder/regulatory/default.htm (score=34)

A Dose of Clear Directions for Rx Drug Users
...Under the action plan, health professionals will voluntarily provide prescription drug.....instructions for proper use, including the usual doses, instructions if a scheduled dose.....Useful prescription drug information must reach at least 75 percent of patients by the year..
http://www.fda.gov/fdac/features/1997/597_drug.html (score=34)

Document
...to convene a panel of pediatric experts, existing drug advisory committees, FDA agrees.....1 In one case, pediatric use information provided for one of two approved indications.2 In.....limited information gain. submission of pediatric use information, scientifically, legally..
http://www.fda.gov/ohrms/dockets/98fr/120298c.pdf (score=34)

Microsoft Word - 5341fnl.doc
...pharmacological effect or clinical benefit effect in relation to dose or drug concentration.The.....responses at that dose, but do not provide information about the distribution of individual dose-response.....subsequent titration steps based on response to the drug, as well as information on how to..
http://www.fda.gov/cder/guidance/5341fnl.pdf (score=33)

/a//content.23634
...confirmatory characterization of safety and/ Phase II that a drug is safe and effective.....present data, information, or views, Lane, Rockville, MD 20857, 301­827­ Manufacturers.....tolerability of the dose range expected to be.. duration of drug exposure in patients at..
http://www.fda.gov/cder/guidance/1857fnl.pdf (score=33)

Kaletra Information
...Lopinavir's antiviral properties are combined with a low dose of ritonavir that inhibits.....The new drug is used in combination with other anti-HIV drugs. It should be taken with.....The usual dose for adults is three capsules or 5.0 mL twice a day. Dosing for children..
http://www.fda.gov/cder/drug/infopage/kaletra/default.htm (score=33)

Reviewer Guidance: Evaluation of Human Pregnancy Outcome Data
...includes information about the exposure itself including dose, duration, and gestational.....3 Throughout this document, the term drug includes therapeutic biological agents and.....information more broadly, including information that relates to toxicities that may be..
http://www.fda.gov/cber/gdlns/rvrpreg.pdf (score=32)

Las Vegas Injury Lawyer